Dyfyniad APA

Kijak, G., Ahani, B., Arbetter, D., Chuecos, F., Gopalakrishnan, V., Beloor, J., . . . Streicher, K. (2023). Analysis of SARS-CoV-2 Emergent variants following AZD7442 (tixagevimab/cilgavimab) for early outpatient treatment of COVID-19 (TACKLE trial). Springer Nature.

Dyfyniad Arddull Chicago

Kijak, GH, et al. Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (tixagevimab/cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial). Springer Nature, 2023.

Dyfyniad MLA

Kijak, GH, et al. Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (tixagevimab/cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial). Springer Nature, 2023.

Rhybudd: Mae'n bosib nad yw'r dyfyniadau hyn bob amser yn 100% cywir.